leisure time -WSS

leisure time

author：entertainment 2025-09-14 18:26:48 - browse：2

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： HPV vaccine, cervical cancer study delivers historic results

WSS

A pediatrician calls for Congress to pass the child tax credit deal

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Micronoma's microbiome cancer diagnostic approach under fire

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Mitch McConnell episode has important public health takeaway

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

hotspot

leisure time

focus

The cancer drug shortage isn’t new — and neither are the solutions

There's an unseen cost to disruptive road

ChatGPT in medicine: STAT answers readers' burning questions

CVS is on a mission to consolidate health care. Will it work?

Affirmative action in medical school literally saved lives

National panel will explore requiring free Covid tests

Affirmative action in medical school literally saved lives

Wildfire pollution widens asthma inequities on Long Island

Hepatitis C has a cure — but many Americans still lack access to it

FDA sets aggressive timeline for overhauling inspection procedures

leisure time

Flu vaccine reformulation won't be easy, manufacturers warn

The high personal cost of affirmative action for Black doctors

Flu vaccine reformulation won't be easy, manufacturers warn

National panel will explore requiring free Covid tests

Dana Farber says 6 studies to be retracted and 31 corrected

Vertex non

entertainment

knowledge

Wikipedia

focus